Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Source: 
Endpoints
snippet: 

A busy clinical team at Regeneron $REGN and Sanofi $SNY has outlined another segment on the allergic inflammatory map that they plan to build their Dupixent kingdom upon.

In two Phase III trials, investigators say, the mega-blockbuster hopeful delivered a clean sweep over chronic rhinosinusitis with nasal polyps, clearing obstruction and shrinking abnormal tissue growth at a much higher rate than placebo.